Meeting
2022 ASCO Annual Meeting
Reversion mutations in BRCA1 or BRCA2 genes: Resistant mechanism(s) in patients treated with platinum-based agents or poly (ADP-ribose) polymerase(PARP) inhibitors.
Authors
Sourat Darabi
Hoag Family Cancer Institute, Newport Beach, CA
Sourat Darabi , David R. Braxton , Joanne Xiu , Benedito A. Carneiro , Jeffrey Swensen , Emmanuel S. Antonarakis , Stephen V. Liu , Rana R. McKay , David Spetzler , Wafik S. El-Deiry , Michael J. Demeure
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3132)
DOI
10.1200/JCO.2022.40.16_suppl.3132
Abstract #
3132
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.
First Author: Ruben Raychaudhuri
Poster
2022 ASCO Annual Meeting
A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.
First Author: Timothy J Brown
Poster
2021 Genitourinary Cancers Symposium
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).
First Author: Fadi Taza
Poster
2020 Genitourinary Cancers Symposium
Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jacob E Berchuck